Business Context and Reporting Period
Company: Alterity Therapeutics Ltd
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: February 2020 (Filed February 7, 2020)
Principal Executive Office: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of a regulatory event rather than a financial statement.
Material Changes
The registrant received a NASDAQ Non-Compliance Notice. The filing does not specify the exact nature of the non-compliance (e.g., minimum bid price, shareholder equity, or listing rule violations) within the provided text.
Guidance, Outlook, and Risks
Management Commentary: None provided in the text.
Risks and Contingencies: The receipt of a NASDAQ Non-Compliance Notice poses a risk to the company's continued listing status on the NASDAQ stock market if the issue is not resolved within the timeframe specified by the exchange.
Investor Verification Checklist
- Verify the specific reason for the NASDAQ Non-Compliance Notice (e.g., stock price, market cap, or corporate governance).
- Check for subsequent filings detailing the company's plan to regain compliance.
- Confirm the current trading status of the company's shares on NASDAQ.
- Review the company's most recent Form 20-F for baseline financial health to assess the impact of the compliance issue.